Back to Search Start Over

Design of surface ligands for blood compatible gold nanoparticles: Effect of charge and binding energy.

Authors :
Beurton, Jordan
Lavalle, Philippe
Pallotta, Arnaud
Chaigneau, Thomas
Clarot, Igor
Boudier, Ariane
Source :
International Journal of Pharmaceutics. Apr2020, Vol. 580, pN.PAG-N.PAG. 1p.
Publication Year :
2020

Abstract

• Weakly stabilized and positively charged AuNP aggregate with proteins. • Antifouling ability carried by strongly capped, neutral and negatively charged AuNP. • Hemolysis increased by weakly stabilized and positively charged particles. • Hemolysis decreased by strongly capped and negatively charged particles. Gold nanoparticle (AuNP) interaction with the blood compartment as a function of their charge and the binding energy of their surface ligand was explored. Citrate, polyallylamine and cysteamine stabilized AuNP along with dihydrolipoic acid and polyethylene glycol capped AuNP were synthesized and fully characterized. Their interactions with model proteins (human albumin and human fibrinogen) were studied. Complexes formed between AuNP and protein revealed several behaviors ranging from corona formation to aggregation. Protein fluorescence quenching as a function of temperature and AuNP concentration allowed the determination of the thermodynamic parameters describing these interactions. The hemolysis induced by AuNP was also probed: an increasing or a decreasing of hemolysis ratio induced by AuNP was observed as of function of protein corona formation. Taken together, our results drew up a composite sketch of an ideal surface ligand for blood compatible AuNP. This capping agent should be strongly bound to the gold core by one or more thiol groups and it must confer a negative charge to the particles. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03785173
Volume :
580
Database :
Academic Search Index
Journal :
International Journal of Pharmaceutics
Publication Type :
Academic Journal
Accession number :
142668889
Full Text :
https://doi.org/10.1016/j.ijpharm.2020.119244